![](/coreweb/template1/pix/main_left_bg.gif) |
![](/coreweb/template1/pix/pixel.gif) |
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Oct 23, 2018 |
Title |
SMAD2 binding regions in triple negative breast cancer cell line, Hs578T |
Organism |
Homo sapiens |
Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
Inhibitors for cyclin-dependent kinase (CDK) 4 and CDK6 have been established as effective therapeutic options for hormone receptor (HR)-positive, HER2-negative advanced breast cancer. Although the CDK4/6 inhibitors mainly target the cyclin D-CDK4/6-retinoblastoma tumor suppressor protein (RB) axis, little is known about clinical impact of inhibiting phosphorylation of other CDK4/6 target proteins. Here, we have focused on other CDK4/6 targets, SMAD proteins. We showed that a CDK4/6 inhibitor Palbociclib and Activin-SMAD2 signaling cooperatively inhibited cell cycle progression of a luminal-type breast cancer cell line T47D. Mechanistically, Palbociclib enhanced SMAD2 binding to the genome through inhibiting linker phosphorylation of the SMAD2 protein by CDK4/6. Comparison of the SMAD2 ChIP-seq data of T47D with those of a triple-negative breast cancer cell line Hs578T indicated that Palbociclib augments different SMAD2-mediated program defined based on types of cells, and enhances SMAD2 binding to the target regions on the genome without affecting its binding pattern. Collectively, the CDK4/6 inhibitor facilitates the cytostatic effects of Activin-SMAD2, while it also enhances its tumor promoting effects depending on types of breast cancer.
|
|
|
Overall design |
SMAD2 ChIP-seq analysis was performed in triple negative breast cancer after Activin A with/without Palbociclib treatment
|
|
|
Contributor(s) |
Harada M, Morikawa M, Ozawa T, Tamura Y, Miyazono K, Koinuma D |
Citation(s) |
30343527 |
Submission date |
Jul 23, 2018 |
Last update date |
Mar 01, 2019 |
Contact name |
Daizo Koinuma |
E-mail(s) |
d-koinuma@umin.ac.jp
|
Organization name |
University of Tokyo
|
Department |
Pathology
|
Street address |
Hongo 7-3-1, Bunkyo-ku
|
City |
Tokyo |
ZIP/Postal code |
113-0033 |
Country |
Japan |
|
|
Platforms (1) |
GPL17303 |
Ion Torrent Proton (Homo sapiens) |
|
Samples (6)
|
GSM3301952 |
Hs578T, SMAD2 binding region after ActA stimulation rep1 |
GSM3301953 |
Hs578T, SMAD2 binding region after ActA stimulation and Palbo treatment rep1 |
GSM3301954 |
Hs578T, SMAD2 binding region after ActA stimulation rep2 |
GSM3301955 |
Hs578T, SMAD2 binding region after ActA stimulation and Palbo treatment rep2 |
GSM3301956 |
Hs578T, input_ActA |
GSM3301957 |
Hs578T, input_ActA_Palbo |
|
This SubSeries is part of SuperSeries: |
GSE117502 |
SMAD2 binding regions in breast cancer cell line and RNA-seq transcriptome analyses in T47D |
|
Relations |
BioProject |
PRJNA482343 |
SRA |
SRP154854 |
Supplementary file |
Size |
Download |
File type/resource |
GSE117496_RAW.tar |
254.6 Mb |
(http)(custom) |
TAR (of BED, BW) |
SRA Run Selector![Help](/coreweb/images/long_help4.gif) |
Raw data are available in SRA |
Processed data provided as supplementary file |
|
|
|
|
![](/coreweb/template1/pix/main_right_bg.gif) |